Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the equity markets continued their rally, fueled by enthusiasm for AI, limited evidence of inflationary effects from tariffs, and expectations for further interest rate cuts from the U.S. Federal Reserve. Mid-cap stocks also maintained their positive gains during the quarter. The Russell Midcap Growth Index (up 2.78%) underperformed the Russell Midcap® Value Index (up 6.16%) in the quarter. The letter further shared the firm's detailed views on Cyclicals, Healthcare, Information Technology, Financials, and Consumer sectors. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.
In its third-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks such as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers and commercializes therapeutics based on ribonucleic acid interference. The one-month return of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was -8.76%, and its shares gained 71.40% of their value over the last 52 weeks. On November 24, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock closed at $434.23 per share, with a market capitalization of $57.368 billion.
Carillon Eagle Mid Cap Growth Fund stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its third quarter 2025 investor letter:
"Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading company focused on developing gene-silencing technologies to address significant unmet medical needs. The launch of vutrisiran for transthyretin (TTR) amyloidosis exceeded expectations, with second-quarter sales coming in well above consensus expectations. The company also substantially raised its TTR sales guidance, which drove the stock higher."
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge fund portfolios held Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at the end of the second quarter, which was 59 in the previous quarter. In the third quarter of 2025, the product revenue of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew 103% year-over-year to $851 million. While we acknowledge the potential of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.
Content Original Link:
" target="_blank">
